Hémangiome sclérosant du poumon : Questions médicales fréquentes
Nom anglais: Pulmonary Sclerosing Hemangioma
Descriptor UI:D047868
Tree Number:C08.785.520.867
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hémangiome sclérosant du poumon : Questions médicales les plus fréquentes",
"headline": "Hémangiome sclérosant du poumon : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hémangiome sclérosant du poumon : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-17",
"dateModified": "2025-04-13",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs du poumon",
"url": "https://questionsmedicales.fr/mesh/D008175",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du poumon",
"code": {
"@type": "MedicalCode",
"code": "D008175",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C08.785.520"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Hémangiome sclérosant du poumon",
"alternateName": "Pulmonary Sclerosing Hemangioma",
"code": {
"@type": "MedicalCode",
"code": "D047868",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Weidong Zhang",
"url": "https://questionsmedicales.fr/author/Weidong%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Department of Cardiothoracic Surgery, Henan Provincial Chest Hospital (Chest Hospital of Zhengzhou University), Zhengzhou, Henan, China. zhangweidong0371@126.com."
}
},
{
"@type": "Person",
"name": "Tae Wook Kang",
"url": "https://questionsmedicales.fr/author/Tae%20Wook%20Kang",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dong Ik Cha",
"url": "https://questionsmedicales.fr/author/Dong%20Ik%20Cha",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Seong Hyun Kim",
"url": "https://questionsmedicales.fr/author/Seong%20Hyun%20Kim",
"affiliation": {
"@type": "Organization",
"name": "From the Department of Radiology and Center for Imaging Science, Samsung Medical Center, School of Medicine, Sungkyunkwan University, Seoul."
}
},
{
"@type": "Person",
"name": "Dan Song",
"url": "https://questionsmedicales.fr/author/Dan%20Song",
"affiliation": {
"@type": "Organization",
"name": "Department of Vascular Anomalies and Interventional Radiology, Jinan Children's Hospital, Qilu Children's Hospital of Shandong University, Jinan, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Treatment and post-operative follow-up of pulmonary sclerosing pneumocytoma: A case report.",
"datePublished": "2022-11-05",
"url": "https://questionsmedicales.fr/article/36582872",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.amsu.2022.104836"
}
},
{
"@type": "ScholarlyArticle",
"name": "Solitary Pulmonary Capillary Hemangioma: CT and PET-CT Features with Clinicopathologic Correlation.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/36359462",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/diagnostics12112618"
}
},
{
"@type": "ScholarlyArticle",
"name": "Spontaneous remission of a pulmonary sclerosing epithelioid fibrosarcoma: a case report of a possible abscopal effect.",
"datePublished": "2024-05-21",
"url": "https://questionsmedicales.fr/article/38881927",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.21037/tcr-23-2276"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pulmonary sclerosing pneumocytoma - rare diagnosis in a Caucasian woman: case report and review of the literature.",
"datePublished": "2024-06-13",
"url": "https://questionsmedicales.fr/article/39091433",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/20542704231200394"
}
},
{
"@type": "ScholarlyArticle",
"name": "CT-based radiomics for differentiating peripherally located pulmonary sclerosing pneumocytoma from carcinoid.",
"datePublished": "2024-03-20",
"url": "https://questionsmedicales.fr/article/38507783",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/mp.17037"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Maladies de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012140"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs de l'appareil respiratoire",
"item": "https://questionsmedicales.fr/mesh/D012142"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs du poumon",
"item": "https://questionsmedicales.fr/mesh/D008175"
},
{
"@type": "ListItem",
"position": 5,
"name": "Hémangiome sclérosant du poumon",
"item": "https://questionsmedicales.fr/mesh/D047868"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hémangiome sclérosant du poumon - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hémangiome sclérosant du poumon",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hémangiome sclérosant du poumon",
"description": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?\nQuels examens sont recommandés pour confirmer le diagnostic ?\nLes symptômes influencent-ils le diagnostic ?\nPeut-on confondre cette tumeur avec d'autres lésions ?\nQuel rôle joue la biopsie dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D047868?page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hémangiome sclérosant du poumon",
"description": "Quels sont les symptômes courants de l'hémangiome sclérosant ?\nL'hémangiome sclérosant cause-t-il des difficultés respiratoires ?\nPeut-on avoir des symptômes sans lésion visible ?\nLes symptômes varient-ils selon l'âge ?\nY a-t-il des symptômes spécifiques à surveiller ?",
"url": "https://questionsmedicales.fr/mesh/D047868?page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hémangiome sclérosant du poumon",
"description": "Peut-on prévenir l'hémangiome sclérosant du poumon ?\nY a-t-il des facteurs de risque connus ?\nLes habitudes de vie influencent-elles le risque ?\nLes examens réguliers aident-ils à la détection précoce ?\nLes femmes sont-elles plus à risque ?",
"url": "https://questionsmedicales.fr/mesh/D047868?page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hémangiome sclérosant du poumon",
"description": "Quel est le traitement standard pour l'hémangiome sclérosant ?\nPeut-on traiter cette condition par des médicaments ?\nQuand est-il nécessaire de surveiller sans traiter ?\nQuels sont les risques associés à la chirurgie ?\nY a-t-il des traitements alternatifs ?",
"url": "https://questionsmedicales.fr/mesh/D047868?page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hémangiome sclérosant du poumon",
"description": "Quelles complications peuvent survenir ?\nL'hémangiome peut-il se transformer en cancer ?\nComment gérer les complications respiratoires ?\nLes complications sont-elles fréquentes ?\nY a-t-il des complications post-chirurgicales ?",
"url": "https://questionsmedicales.fr/mesh/D047868?page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hémangiome sclérosant du poumon",
"description": "Quels sont les principaux facteurs de risque ?\nL'exposition à des toxines augmente-t-elle le risque ?\nLes antécédents médicaux influencent-ils le risque ?\nLe tabagisme est-il un facteur de risque ?\nLes facteurs génétiques jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D047868?page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostique-t-on un hémangiome sclérosant du poumon ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'imagerie, notamment la tomodensitométrie (TDM) et la biopsie."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour confirmer le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "La TDM thoracique et l'IRM peuvent aider à visualiser la lésion et son caractère bénin."
}
},
{
"@type": "Question",
"name": "Les symptômes influencent-ils le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent être absents, rendant le diagnostic souvent incident lors d'examens pour d'autres raisons."
}
},
{
"@type": "Question",
"name": "Peut-on confondre cette tumeur avec d'autres lésions ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut être confondue avec d'autres tumeurs pulmonaires, nécessitant une analyse approfondie."
}
},
{
"@type": "Question",
"name": "Quel rôle joue la biopsie dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "La biopsie permet de confirmer la nature bénigne de la lésion et d'exclure d'autres pathologies."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants de l'hémangiome sclérosant ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Souvent asymptomatique, il peut provoquer une toux ou des douleurs thoraciques dans certains cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome sclérosant cause-t-il des difficultés respiratoires ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Rarement, mais des complications peuvent entraîner des difficultés respiratoires dans certains cas."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans lésion visible ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent survenir sans lésion visible, rendant le diagnostic plus complexe."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon l'âge ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes ne varient pas significativement selon l'âge, car la plupart des cas sont asymptomatiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes spécifiques à surveiller ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Surveillez la toux persistante ou des douleurs thoraciques, bien que souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir l'hémangiome sclérosant du poumon ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de mesures préventives spécifiques pour cette condition bénigne."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs de risque connus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas clairement établis, mais des antécédents familiaux peuvent jouer un rôle."
}
},
{
"@type": "Question",
"name": "Les habitudes de vie influencent-elles le risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve directe ne lie les habitudes de vie au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les examens réguliers aident-ils à la détection précoce ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des examens réguliers peuvent aider à détecter des anomalies, mais l'hémangiome est souvent asymptomatique."
}
},
{
"@type": "Question",
"name": "Les femmes sont-elles plus à risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines études suggèrent une prévalence plus élevée chez les femmes, mais les données sont limitées."
}
},
{
"@type": "Question",
"name": "Quel est le traitement standard pour l'hémangiome sclérosant ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement est généralement chirurgical si la tumeur est symptomatique ou suspecte."
}
},
{
"@type": "Question",
"name": "Peut-on traiter cette condition par des médicaments ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il n'existe pas de traitement médicamenteux spécifique, la chirurgie est la principale option."
}
},
{
"@type": "Question",
"name": "Quand est-il nécessaire de surveiller sans traiter ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Si la tumeur est asymptomatique et bénigne, une surveillance régulière peut suffire."
}
},
{
"@type": "Question",
"name": "Quels sont les risques associés à la chirurgie ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les risques incluent des infections, des saignements et des complications respiratoires post-opératoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements alternatifs ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements alternatifs ne sont pas prouvés efficaces et ne remplacent pas la chirurgie."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des infections pulmonaires et des hémorragies dans de rares cas."
}
},
{
"@type": "Question",
"name": "L'hémangiome peut-il se transformer en cancer ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'hémangiome sclérosant est une tumeur bénigne et ne se transforme pas en cancer."
}
},
{
"@type": "Question",
"name": "Comment gérer les complications respiratoires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications respiratoires doivent être traitées symptomatiquement et surveillées attentivement."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares, la plupart des cas étant asymptomatiques et sans incidents."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications post-chirurgicales ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme des infections ou des saignements peuvent survenir après la chirurgie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs de risque ne sont pas bien définis, mais des antécédents familiaux peuvent être impliqués."
}
},
{
"@type": "Question",
"name": "L'exposition à des toxines augmente-t-elle le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Aucune preuve solide ne lie l'exposition à des toxines au développement de l'hémangiome sclérosant."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents médicaux ne semblent pas avoir d'impact direct sur le développement de cette tumeur."
}
},
{
"@type": "Question",
"name": "Le tabagisme est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le lien entre tabagisme et hémangiome sclérosant n'est pas clairement établi dans la littérature."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que des facteurs génétiques peuvent influencer le développement de l'hémangiome."
}
}
]
}
]
}
Pulmonary sclerosing pneumocytoma (PSP) is a rare tumor thought to originate from respiratory epithelial cells. It is usually benign, but may rarely metastasize to lymph nodes. Surgeons face unique ch...
48-year-old woman with a 7 × 7 mm pulmonary lesion discovered incidentally on computerized tomography (CT) imaging, which grew to 9 mm over the following year. Seven years later, follow-up imaging rev...
There are few evidence-based guidelines available on the treatment and postoperative surveillance of PSP. Research has shown comparable recurrence-free survival rates for sublobar resection and lobect...
This case report adds to the limited literature on PSP and depicts a possible treatment and postoperative follow-up plan. Right VATS middle lobectomy can effectively treat some cases of central PSP. I...
The aim of this study was to evaluate the CT and PET-CT features of solitary pulmonary capillary hemangioma (SPCH) with clinicopathologic correlations. This retrospective study included 17 patients wi...
Spontaneous remission (SR) is defined as the complete or partial disappearance of a diagnosed malignant disease in the absence of known active medical treatment. The role of the immune system is thoug...
We present the case of a patient with a lung metastatic recurrence of SEF, diagnosed and treated with surgery 8 years before. After progression to pazopanib and other ChT drugs, because of the chest p...
As far as reported in the literature, this is the first case of SR in SEF. Among the possible causes of this SR, we think that the most plausible is that palliative treatment with RT of the pleural ma...
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign pulmonary tumour, most reported cases of PSP are from Eastern Asia, with a female to male ratio of 5:1, and average age at diagnosis in the 5...
Pulmonary sclerosing pneumocytoma (PSP) and pulmonary carcinoid (PC) are difficult to distinguish based on conventional imaging examinations. In recent years, radiomics has been used to discriminate b...
We aimed to investigate the feasibility of radiomics in the differentiation between PSP and PC....
Fifty-three PSP and fifty-five PC were retrospectively enrolled and then were randomly divided into the training and test sets. Univariate and multivariable logistic analyses were carried to select cl...
In regard to differentiating PSP from PC, the area under the curves (AUCs) of the clinical, radiomics, and combined models were 0.87, 0.96, and 0.99 in the training set UECT, and were 0.87, 0.97, and ...
Radiomics approaches show promise in distinguishing between PSP and PC. Moreover, the integration of clinical predictor (gender) has the potential to enhance the diagnostic performance even further....
Pulmonary sclerosing pneumocytoma (PSP) is a rare lung tumor that is mostly isolated and commonly reported among middle-aged East Asian women. Recently, Immunohistochemistry (IHC) analysis has suggest...
We reported a case of an asymptomatic 56-year-old female with a solitary, well-defined soft-tissue mass in the lower lobe of the left lung. The mass showed iso-to-high signal intensity (SI) than muscl...
The MRI findings of PSP correspond to its histopathological features. Here, we present a case of PSP with the most comprehensive MRI findings, emphasizing the importance of multiple-sequence MRI in di...
To analyze the clinical characteristics of patients with malignant pulmonary sclerosing pneumocytoma (PSP) with metastasis, recurrence, and growth and to improve clinicians' understanding of PSP in pa...
A total of 46 PSP patients with malignant tumor characteristics were identified in the literature search and compared with 38 patients with benign PSP diagnosed and treated in our hospital in the past...
The characteristics of young age (≤41 years old), larger tumor (≥36mm), lymph node metastasis and distribution in East Asians are indicative of PSP with malignant potential. Such patients should under...
PSP has the potential for malignancy. Anatomical lobectomy or segmental resection combined with lymph node dissection should be performed in PSP with some specific characteristics. Inappropriate diagn...
Sclerosing cholangitis is a chronic cholestatic disease characterized by stricturing, beading, and obliterative fibrosis of the bile ducts. Sclerosing cholangitis is considered primary (PSC) if no und...
Pulmonary sclerosing pneumocytoma (PSP) is a rare, benign tumor. Given the challenges of a bronchoscopic diagnosis, surgery is performed during the early stages of the disease. Therefore, little is kn...
Pulmonary sclerosing pneumocytoma (PSP) is a rare benign lung tumor which generally presents as a solitary pulmonary nodule in middle-aged females. However, the PSP in some patients exhibits potential...
We encountered a case of a 46-year-old female with an inordinately massive tumor 9.5 cm in diameter and a relatively high Ki-67 proliferation rate. Fine needle aspiration (FNA) played a significant bu...
PSP lacks specificity in its clinical and radiological characteristics and has complex pathological manifestations. FNA is valuable in the diagnosis and differential diagnosis of PSP but involves the ...